Myasthenia gravis: Frequently asked questions

Myasthenia gravis is a disorder of neuromuscular junction transmission, the result of antibodies against the post-synaptic aspect of the neuromuscular junction. Its clinical hallmark is fatigable weakness of skeletal muscles, which tends to vary in location and severity among patients. It is treated...

Full description

Saved in:

Bibliographic Details
Published in:	Cleveland Clinic journal of medicine Vol. 90; no. 2; pp. 103 - 113
Main Authors:	Morren, John A, Li, Yuebing
Format:	Journal Article
Language:	English
Published:	United States 01-02-2023
Subjects:	Humans Muscle Weakness - etiology Muscle, Skeletal Myasthenia Gravis - diagnosis Myasthenia Gravis - therapy
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Myasthenia gravis is a disorder of neuromuscular junction transmission, the result of antibodies against the post-synaptic aspect of the neuromuscular junction. Its clinical hallmark is fatigable weakness of skeletal muscles, which tends to vary in location and severity among patients. It is treated with pyridostigmine, immunotherapy, and thymectomy. Treatment is often individualized according to disease severity, antibody status, comorbidities, and other factors. This review uses a question-and-answer format to provide up-to-date, high-yield, clinically relevant information on myasthenia gravis.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1
ISSN:	0891-1150 1939-2869
DOI:	10.3949/ccjm.90a.22017